查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1969952

2026-2034年全球小細胞肺癌（SCLC）治療市場規模、佔有率、趨勢和成長分析報告

Global Small Cell Lung Cancer (SCLC) Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

小細胞肺癌 (SCLC) 治療市場規模預計將從 2025 年的 187.8 億美元成長到 2034 年的 455.3 億美元，2026 年至 2034 年的複合年成長率為 10.34%。

由於全球肺癌發生率不斷上升，小細胞肺癌（SCLC）治療的全球市場正在成長，尤其是在吸菸者和高危險群中。 SCLC是一種侵襲性很強的癌症，需要即時進行強化治療。人們對早期癌症檢測意識提升以及診斷技術的進步，都有助於提高治療率。

關鍵成長要素包括免疫療法、標靶治療和聯合治療的研發。製藥公司正大力投資研發，旨在提高存活率並減少副作用。臨床試驗的擴展和新藥的監管核准正在加速市場成長。此外，政府對癌症研究的支持也加強了小細胞肺癌治療領域的創新。

未來幾年，小細胞肺癌（SLC）治療市場可望受惠於個人化治療方案和精準腫瘤學的發展。生物標記檢測技術的進步將有助於選擇更有效的治療方法。新興市場獲得先進癌症療法的機會增加也創造了新的成長機會。隨著持續的創新和全球癌症意識的不斷提高，市場前景仍然非常樂觀。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球小細胞肺癌（SCLC）治療市場：依治療類型分類

  • 市場分析、洞察與預測
  • 化療
  • 標靶治療
  • 其他

第5章 全球小細胞肺癌（SCLC）治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 靜脈注射
  • 其他

第6章 全球小細胞肺癌（SCLC）治療市場：依最終使用者分類

  • 市場分析、洞察與預測
  • 醫院
  • 居家照護
  • 專業治療機構
  • 其他

第7章 全球小細胞肺癌（SCLC）治療市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章 全球小細胞肺癌（SCLC）治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd
    • Sanofi
    • Pfizer Inc
    • GSK Plc
    • Novartis AG
    • Bayer AG
    • Lilly
    • Merck & Co. Inc
    • Sun Pharmaceutical Industries Ltd
    • Aurobindo Pharma
    • Lupin
    • Clovis Oncology
    • Johnson & Johnson Private Limited
簡介目錄
Product Code: VMR112110674

The Small Cell Lung Cancer (SCLC) Therapeutics Market size is expected to reach USD 45.53 Billion in 2034 from USD 18.78 Billion (2025) growing at a CAGR of 10.34% during 2026-2034.

The Global Small Cell Lung Cancer (SCLC) Therapeutics Market is growing due to the rising prevalence of lung cancer worldwide, particularly among smokers and high-risk populations. Small cell lung cancer is an aggressive form of cancer that requires immediate and intensive treatment. Increased awareness about early cancer detection and advancements in diagnostic techniques are contributing to higher treatment adoption rates.

Major growth drivers include the development of immunotherapies, targeted therapies, and combination treatment regimens. Pharmaceutical companies are investing heavily in research to improve survival rates and reduce side effects. Expanding clinical trials and regulatory approvals for novel drugs are accelerating market growth. Additionally, supportive government funding for cancer research is strengthening innovation in the SCLC treatment landscape.

In the coming years, the SCLC therapeutics market is expected to benefit from personalized treatment approaches and precision oncology. Advancements in biomarker testing will enable more effective therapy selection. Emerging markets are also improving access to advanced cancer care, creating new growth opportunities. With continuous innovation and increasing global cancer awareness, the market outlook remains highly positive.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

  • Chemotherapy
  • Targeted Therapy
  • Others

By Route of Administration

  • Intravenous
  • Others

By End-Users

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

COMPANIES PROFILED

  • F HoffmannLa Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK plc, Novartis AG, Bayer AG, Lilly, Merck Co Inc, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin, Clovis Oncology, Johnson Johnson Private Limited
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment Type
  • 4.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Route Of Administration
  • 5.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS MARKET: BY END-USERS 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End-users
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Speciality Centres Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Treatment Type
    • 8.2.2 By Route Of Administration
    • 8.2.3 By End-users
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Treatment Type
    • 8.3.2 By Route Of Administration
    • 8.3.3 By End-users
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Treatment Type
    • 8.4.2 By Route Of Administration
    • 8.4.3 By End-users
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Treatment Type
    • 8.5.2 By Route Of Administration
    • 8.5.3 By End-users
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Treatment Type
    • 8.6.2 By Route Of Administration
    • 8.6.3 By End-users
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 F. Hoffmann-La Roche Ltd
    • 10.2.2 Mylan N.V
    • 10.2.3 Teva Pharmaceutical Industries Ltd
    • 10.2.4 Sanofi
    • 10.2.5 Pfizer Inc
    • 10.2.6 GSK Plc
    • 10.2.7 Novartis AG
    • 10.2.8 Bayer AG
    • 10.2.9 Lilly
    • 10.2.10 Merck & Co. Inc
    • 10.2.11 Sun Pharmaceutical Industries Ltd
    • 10.2.12 Aurobindo Pharma
    • 10.2.13 Lupin
    • 10.2.14 Clovis Oncology
    • 10.2.15 Johnson & Johnson Private Limited